Welcome to the
European Biotechnology Network!

The European Biotechnology Network is dedicated to facilitating co-operation between professionals in biotechnology and the life sciences all over Europe.

The non-profit organisation brings research groups, universities, SMEs, large companies and indeed all actors in biotechnology together to build and deliver partnerships.

Read more about our activities here.

Latest Catch

  • © Innate Pharma

    AZ and Innate in €1.2bn immuno-oncology deal

    24.04.2015 AstraZeneca has boosted its oncology portfolio by signing a US$1.275bn agreement with Innate Pharma. The companies plan to further the development of Innate’s tumour-targeting antibody.

    Under the terms of the co-development and commercialisation agreement, the Marseille-based biotech will receive cash payments of up to US$1.275bn (€1.17bn) as well as double digit royalties on sales. AstraZeneca and its biologics R&D arm Medimmune gain exclusive global rights to co-develop and commercialise IPH2201 in combination with MEDI473, an anti-PD-L1 immune checkpoint inhibitor developed by MedImmune. The Swedish-British pharma giant also gains access to IPH2201 in monotherapy and other combinations in certain areas.

    In addition to an initial payment of US$250m (€230m), AstraZeneca will grant further regulatory and sales-related milestones of up to US$925m (€851m). AstraZeneca will book all sales and will pay Innate double-digit royalties on net sales. Innate retains the right to co-promote in Europe with a 50% profit share in the territory.

    Currently in Phase II development, IPH2201 is a potential first-in-class humanised anti-NKG2A antibody. The checkpoint receptor NKG2A inhibits the anti-cancer functions of Natural Killer (NK) and cytotoxic cells.

    © european-biotechnology-news.com/jc

    The Latest Catch is brought to you by European Biotechnology News

Featured Events

Our Corporate Members are


All events


European Biotechnology Network

Avenue de Tervueren 13
1040 Brussels, Belgium

Tel: +32 27 33 72 37


Join the European Biotechnology Network!

Individual Membership for natural persons is free, while Corporate Membership, for companies, institutions and research groups start from €500 p.a.

Click here to apply for network membership!

Funding Hub Strategic Partnership

European Biopharmaceutical Enterprises